Vagus nerve stimulation devices range from surgically implanted pulse generators approved for epilepsy and depression to handheld non-invasive units cleared for migraine and cluster headache, to consumer-grade transcutaneous devices with varying levels of evidence behind them. The landscape has expanded significantly since 2020, and understanding what each category of device actually does — and what the evidence supports — matters for anyone considering VNS therapy.
Implanted VNS (iVNS)
Implanted vagus nerve stimulation remains the most extensively studied form. The LivaNova VNS Therapy system (formerly Cyberonics) is a surgically implanted pulse generator placed subcutaneously below the left clavicle, with a helical electrode wrapped around the left cervical vagus nerve. It delivers programmable electrical pulses — typically 20-30 Hz, 250-500 microsecond pulse width, 0.25-3.5 mA current — on a duty cycle of 30 seconds on, 5 minutes off.
Epilepsy. iVNS has been FDA-approved for drug-resistant epilepsy since 1997. Long-term data from the largest patient registries show that approximately 50% of patients achieve at least 50% seizure reduction after two years of therapy, with efficacy continuing to improve over the first 18-24 months of use. Complete seizure freedom is achieved in approximately 8-10% of patients. The newer SenTiva generator includes cardiac-based seizure detection (AutoStim) that can deliver an additional burst when tachycardia suggesting a seizure onset is detected.
Treatment-resistant depression. iVNS received FDA approval for treatment-resistant depression in 2005, though this remains more controversial than the epilepsy indication. The five-year RESTORE-LIFE registry data showed that 67.6% of patients with treatment-resistant depression responded to adjunctive iVNS therapy at five years, significantly better than treatment-as-usual controls. However, the initial randomised trial was negative at its primary endpoint (10 weeks), and the positive long-term data are from an open-label registry, raising methodological questions.
Limitations. Implantation requires general anaesthesia and carries surgical risks including infection (3-6%), vocal cord paresis from intraoperative nerve manipulation (1%), and device-related complications. The generator battery lasts 3-8 years depending on settings and must be surgically replaced. Common side effects include hoarseness during stimulation (which affects most patients initially), cough, and throat discomfort. The system costs approximately $30,000-$40,000 USD for the device alone, plus surgical and programming costs.
Non-Invasive VNS (nVNS): gammaCore
The gammaCore device (electroCore) is a handheld non-invasive vagus nerve stimulator that delivers electrical stimulation transcutaneously to the cervical vagus nerve. The user holds the device against the neck over the vagus nerve and self-administers two-minute stimulation doses. It produces a low-voltage electrical signal (1-30V) with a proprietary waveform.
FDA clearances. gammaCore has accumulated multiple FDA clearances: acute treatment of episodic cluster headache (2017), acute treatment of migraine (2018, based on the PRESTO trial published in Neurology 2019 showing superiority over sham), prevention of migraine (2018, based on the PREMIUM trial), and adjunctive treatment of COVID-19-related respiratory symptoms (2020 Emergency Use Authorization). It also received CE marking in Europe for a broader range of indications.
Clinical evidence for headache. The PRESTO trial demonstrated that gammaCore was significantly more effective than sham stimulation for acute migraine treatment, with 30.4% of patients achieving pain freedom at 2 hours versus 19.7% for sham. For cluster headache, the ACT1 trial showed response rates of 34.2% versus 10.6% for sham in episodic cluster headache, though the device did not show significant benefit over sham in chronic cluster headache.
Mechanism. Cervical nVNS works through the same vagal afferent pathways as implanted VNS. Functional MRI studies have confirmed that gammaCore activates the NTS, locus coeruleus, and trigeminal nucleus — the same brainstem regions activated by implanted VNS. The proposed mechanism for headache involves inhibition of trigeminal nociceptive processing, modulation of descending pain inhibitory pathways, and reduction of cortical spreading depression.
Practical considerations. gammaCore requires a prescription. Each device contains a fixed number of stimulations (typically purchased as 31-day or 93-day supply), after which a new device or refill is needed. The ongoing cost is approximately $500-$600 per month in the US, though insurance coverage has expanded. Side effects are minimal — mild skin irritation, tingling, and occasional muscle twitching at the stimulation site.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Clinician-applied tVNS
- Implanted VNS and neuromodulation
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Transcutaneous Auricular VNS (taVNS)
Transcutaneous auricular vagus nerve stimulation targets the auricular branch of the vagus nerve (ABVN, or Arnold’s nerve), which innervates the cymba conchae of the external ear. This approach is non-invasive and does not require a prescription for consumer-grade devices.
Medical-grade taVNS. The NEMOS device (tVNS Technologies, formerly Cerbomed) is a CE-marked medical taVNS system designed for clinical use. It delivers calibrated stimulation to the cymba conchae via a custom ear electrode. Clinical trials have demonstrated its efficacy in drug-resistant epilepsy (as adjunctive therapy) and in treatment-resistant depression, with the TREAT-tVNS trial showing significant improvement in depression scores after 12 weeks of daily stimulation.
Research-grade taVNS. Numerous academic labs use custom taVNS setups for research. Key findings include: fMRI confirmation that cymba conchae stimulation activates the NTS and connected brainstem nuclei (Frangos et al., 2015); demonstration of anti-inflammatory effects via the cholinergic anti-inflammatory pathway (a 2024 study in Brain Stimulation showed significant TNF-alpha reduction with active versus sham taVNS); and VNS-paired learning paradigms showing enhanced memory consolidation.
Consumer taVNS devices. Several consumer-grade taVNS devices have entered the market, including Pulsetto, Nurosym, and Xen by Neuvana. These devices vary considerably in electrode placement (cymba conchae versus tragus versus earlobe), stimulation parameters, and the strength of their evidence base. Critical distinctions:
The cymba conchae has the highest density of ABVN innervation (confirmed by the Peuker and Filler 2002 cadaveric dissection study). The tragus has mixed innervation from the ABVN and the great auricular nerve. The earlobe has no ABVN innervation and serves as a sham/control location in research. Consumer devices that stimulate only the tragus or earlobe are therefore delivering less — or no — vagal stimulation compared to devices that target the cymba conchae.
Some consumer devices have published pilot data showing changes in HRV or subjective stress measures, but most have not undergone the rigorous sham-controlled trials that medical devices require. Consumers should evaluate specific devices based on: which part of the ear they stimulate, what stimulation parameters they use, and whether they have published any peer-reviewed clinical data.
VNS-Paired Rehabilitation Devices
The MicroTransponder Vivistim system represents a distinct application of VNS — not for direct symptomatic relief but for enhancing neuroplasticity during rehabilitation. Approved by the FDA in 2021 for upper-limb rehabilitation after ischaemic stroke, the system pairs brief bursts of implanted VNS with repetitive task-specific practice. The VNS-REHAB trial (Lancet, 2021) demonstrated significantly greater improvement in arm function compared to rehabilitation with sham stimulation, with benefits maintained at one year. This device uses the same implanted hardware as the LivaNova system but with different stimulation parameters optimised for plasticity rather than seizure control or mood modulation.
Choosing a Device
The appropriate device depends on the clinical indication, severity of the condition, and whether the use is medical treatment or general wellness.
For epilepsy or treatment-resistant depression: implanted VNS has the strongest long-term evidence and should be discussed with a neurologist or psychiatrist who specialises in neuromodulation. taVNS (NEMOS or similar medical-grade devices) may be considered as a less invasive alternative or as a trial before implantation.
For migraine or cluster headache: gammaCore has specific FDA clearances and published trial data for these indications and is the evidence-based non-invasive option.
For general vagal tone improvement, stress reduction, or wellness: consumer taVNS devices may provide benefit, but device selection should prioritise cymba conchae electrode placement and transparent stimulation parameters. These devices should be viewed as tools to enhance — not replace — behavioural vagal practices like breathing exercises, cold exposure, and vocal activation.
For post-stroke rehabilitation: VNS-paired rehabilitation (Vivistim) is a specialised clinical programme that must be delivered in a certified rehabilitation setting, not a home-use device.
VNS devices are one part of the vagus nerve toolkit. For a complete guide to both device-based and natural stimulation approaches, get the Vagus Nerve & Me eBook.
